abstract |
Disclosed is a novel therapeutic agent for cancers, which exhibits an excellent antitumor effect by enhancing the immune system of a cancer patient. The inventors have achieved the present invention by discovering that an excellent antitumor T cell response enhancing effect is obtained by administering an IL-6 inhibitor and/or gemcitabine or a salt thereof to a cancer-bearing living organism. The inventors have also found that an excellent antitumor effect is obtained by the response enhancing effect. |